Singletto Secures $7 Million in Funding to Revolutionize Pathogen Protection with Oxafence® Technology

We are thrilled to announce that Singletto has successfully raised $7 million in our latest funding round, a significant milestone that will propel our mission to redefine safety and wellness in diverse environments. Singletto is at the forefront of innovation with our groundbreaking Oxafence® technology, which provides Active Protection from Pathogens—a critical need in today's world. Our state-of-the-art solution is being tailored for various sectors, including healthcare, military, and industrial applications, as well as for consumers seeking reliable protection against harmful pathogens. This funding will enable us to accelerate our research and development efforts, expand our production capabilities, and enhance our marketing initiatives, ensuring that our revolutionary technology reaches those who need it most. With increasing concerns about health risks in public spaces, the demand for effective pathogen protection solutions has never been more urgent. The investment will also support collaborations with leading institutions to further validate the efficacy of Oxafence® technology, ensuring that it meets the highest standards of quality and safety. At Singletto, we are committed to empowering individuals and organizations with the confidence to live well, knowing they are safeguarded against pathogens. As we chart our course for growth, we invite our partners and stakeholders to join us in creating a safer, healthier future for everyone. Keep an eye on Singletto as we continue to lead the charge in Active Protection and transform how we think about safety and hygiene in our daily lives.